Clinical Specialist - TAVR - AU

About this role

Anteris® Technologies is a global structural heart company dedicated to revolutionizing cardiac care. With offices in Minneapolis, MN, US; Geneva, Switzerland; and Brisbane and Perth, Australia, we have a growing and inclusive team.

Our mission is to forge new frontiers in cardiac care by pioneering science-driven and measurable advancements to restore heart valve patients to healthy function. Transcatheter Aortic Valve Replacement (TAVR) technologies were originally designed for older, high-risk patients. Today, younger, more active patients need a better solution that will not just open and close but restore healthy heart function. We seek to restore healthy blood flow patterns by creating the world’s first biomimetic TAVR valve, DurAVR® THV. This cutting-edge valve, incorporating our proprietary ADAPT® anti-calcification technology, is designed to mimic the natural function of a healthy heart valve.

We are seeking an experienced TAVI Clinical Specialist to play an integral role in supporting the execution of clinical trials while advancing clinical evidence and valve science. The Clinical Specialist will provide procedural and clinical trial case support, contribute to trial enrolment, and identify ongoing educational opportunities for heart team members and the broader referring community. This individual will collaborate closely with Clinical Affairs, Regulatory Affairs, R&D, Quality and Marketing to support optimal clinical outcomes and achieve enrolment objectives aligned with the company’s goals and strategy.

This position may be appointed at varying levels depending on the successful candidate’s qualifications and experience and will report to the Senior Director of Field Operations. The role requires approximately 50–70% domestic and occasional international travel to support trial-related activities and is expected to commence in Q3 / Q4 2026.

At Anteris® Technologies, you will be part of a team dedicated to improving the quality of life for patients with aortic stenosis through groundbreaking medical devices. Join us in our mission to revolutionise structural heart solutions.

Primary Responsibilities:

• Successfully complete the Anteris internal training programme, including demonstrating competency in CT and echocardiographic imaging, the applicable Instructions for Use, procedural best practices, clinical evidence, approved product messaging and the competitive landscape.

• Interface with clinical trial sites, demonstrating expertise in all technical aspects of TAVI clinical case support, training and education, customer service and communication.

• Demonstrate competency in all procedural aspects of DurAVR® THV case support, including valve preparation and loading, device delivery and implantation, complication mitigation and troubleshooting, in accordance with the clinical trial protocol and established best practices.

• Demonstrate a thorough understanding of the approved DurAVR clinical trial protocol, including inclusion and exclusion criteria and requirements for pre- and post-procedure imaging and clinical data.

• Demonstrate proficiency in pre-case planning, CT analysis and pre- and post-procedure recommendations to support optimal clinical outcomes.

• Maintain in-depth knowledge and understanding of existing DurAVR clinical data and the evolving structural heart evidence landscape.

• Support the Clinical and Regulatory Operations teams with site communications, data compliance activities, screening review efficiency and site submission requirements.

• Attend assigned clinical cases and support the heart team with preparation and loading of the DurAVR valve.

• Provide education and guidance to physicians and site personnel regarding the identification of appropriate study participants and support complete and accurate patient screening and enrolment documentation.

• Track patient screening pathway activity and routinely provide site-level metrics related to screening progress and trial enrolment.

• Identify operational improvement opportunities at the site level and recommend strategies to accelerate enrolment, improve efficiency and appropriately advance therapy adoption.